Saltar al contenido
Merck

719927

Sigma-Aldrich

Resomer® RG 756 S, Poly(D,L-lactide-co-glycolide)

ester terminated, lactide:glycolide 75:25, Mw 76,000-115,000

Sinónimos:

PLGA

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula lineal:
[C3H4O2]x[C2H2O2]y
Número de CAS:
Número MDL:
Código UNSPSC:
12162002
NACRES:
NA.23
En este momento no podemos mostrarle ni los precios ni la disponibilidad

Nivel de calidad

Formulario

amorphous

cociente alimentación

lactide:glycolide 75:25

mol peso

Mw 76,000-115,000

marco temporal de la degradación

<6 months

viscosidad

0.71-1.0 dL/g, 0.1 % (w/v) in chloroform(25 °C, Ubbelohde) (size 0c glass capillary viscometer)

temperatura de transición

Tg 49-55 °C

temp. de almacenamiento

2-8°C

cadena SMILES

O2C(C(=O)OC(C2=O)C)C.O1CC(=O)OCC1=O

InChI

1S/C6H8O4.C4H4O4/c1-3-5(7)10-4(2)6(8)9-3;5-3-1-7-4(6)2-8-3/h3-4H,1-2H3;1-2H2

Clave InChI

LCSKNASZPVZHEG-UHFFFAOYSA-N

Aplicación

Controlled release
Poly (lactic-co-glycolic acid) 75:25 copolymer may be used to design a controlled drug delivery implant.[1]

Información legal

Product of Evonik
RESOMER is a registered trademark of Evonik Rohm GmbH

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

An in-situ forming implant formulation of naltrexone with minimum initial burst release using mixture of PLGA copolymers and ethyl heptanoate as an additive: In-vitro, ex-vivo, and in-vivo release evaluation.
Kamali H, et al.
Journal of drug delivery science and technology, 47, 95-105 (2018)
Rongcai Liang et al.
International journal of pharmaceutics, 454(1), 344-353 (2013-07-23)
Peptide or protein degradation often occurs when water flows into the dosage form. The aim of this study was to investigate the effect of water on exenatide acylation in poly(lactide-co-glycolide) (PLGA) microspheres. Exenatide-loaded PLGA microspheres were incubated at different relative
Vanna Sanna et al.
International journal of nanomedicine, 7, 5501-5516 (2012-10-25)
Resveratrol, like other natural polyphenols, is an extremely photosensitive compound with low chemical stability, which limits the therapeutic application of its beneficial effects. The development of innovative formulation strategies, able to overcome physicochemical and pharmacokinetic limitations of this compound, may
Shu-Chun Chuang et al.
Parasites & vectors, 6, 34-34 (2013-02-13)
Current development efforts of subunit vaccines against Toxoplasma gondii, the etiological agent of toxoplasmosis, have been focused mainly on tachyzoite surface antigen 1 (SAG1). Since microparticles made from poly (lactide-co-glycolide) (PLG) polymers have been developed as safe, potent adjuvants or
Maria Kirzhner et al.
Ophthalmology, 120(6), 1300-1304 (2013-02-13)
To compare wrapped and polymer-coated hydroxyapatite implants in children undergoing primary enucleation with no adjuvant therapies. Retrospective, interventional cohort study. All children undergoing primary enucleation without adjuvant therapies between 1999 and 2009 at a tertiary pediatric cancer hospital. Review and

Artículos

Interest in utilizing biodegradable polymers for biomedical applications has grown since the 1960s.

Synthetic aliphatic polyesters dominate resorbable biomaterials in clinical use.

AliAliphatic polyesters, including polylactide and polyglycolide, are biodegradable polymers widely used in medical applications.

Immunosuppressive tumor-associated myeloid cells (TAMC) are responsible for glioblastoma (GBM) resistance to immunotherapies and existing standard of care treatments. This mini-review highlights recent progress in implementing nanotechnology in advancing TAMC-targeted therapies for GBM.

Ver todo

Questions

Reviews

No rating value

Active Filters

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico